CREBBP组蛋白乙酰转移酶结构域突变预测复发/难治性滤泡性淋巴瘤对mTOR抑制的应答
本研究对21例在临床试验中接受mTOR抑制剂依维莫司或替西罗莫司治疗的复发/难治性滤泡性淋巴瘤患者活检标本进行靶向突变分析,发现mTORi应答者中CREBBP催化组蛋白乙酰转移酶(HAT)结构域突变富集,并描述了携带这些突变的FL的独特转录特征和共存突变。
要点
- 在21例接受mTORi治疗的复发/难治性FL患者中,应答者富集CREBBP HAT结构域突变。
- 携带CREBBP HAT突变的FL具有独特的转录特征和共存突变。
- CREBBP HAT突变有望作为FL的治療生物标志物。
核心结论
- 复发/难治性FL中,CREBBP HAT结构域突变在mTORi应答者中富集,支持其作为治疗生物标志物的潜力。
研究设计与样本
- 对21例在临床试验中接受mTORi(依维莫司或替西罗莫司)治疗的复发/难治性FL患者的活检标本进行靶向突变分析。
主要发现
- mTORi应答者中CREBBP催化HAT结构域突变富集。
- 携带CREBBP HAT突变的FL具有独特的转录特征和共存突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker-directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2-mutant FL. Here we examined whether gene mutation status predicts response to clinical mTOR inhibitors (mTORi) in FL, by performing targeted mutational profiling of biopsies from 21 relapsed/refractory FL patients treated with mTORi everolimus or temsirolimus within clinical trials. We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi-responders, and describe distinct transcriptional characteristics and co-occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBPHAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL.
引用
- Kumar EA, Korfi K, Bewicke-Copley F, et al. CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. Br J Haematol. 2024. PMID: 39188028. doi:10.1111/bjh.19671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。